COMy 2021 | A new era of treatment for multiple myeloma
Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, talks on the latest developments in the treatment of multiple myeloma, as discussed at the ‘New era, new data, new implications for managing multiple myeloma’ symposium at ESH MM 2021. The advent of novel induction regimens for transplant-eligible patients was discussed, as well as advances in the standard of care for patients with transplant-ineligible myeloma. Data from several major trials have supported the development of effective combinations for use at the time of relapse, including carfilzomib-daratumumab-dexamethasone, isatuximab-carfilzomib-dexamethasone, and pomalidomide-daratumumab-dexamethasone. The role of immunotherapies was also discussed. This interview took place during the 3rd European Society of Hematology How to Diagnose and Treat Multiple Myeloma (ESH MM) 2021 congress.
Transcript (edited for clarity)
During the last meeting of the European School of Hematology, I had a lovely chat with Professor Philippe Moreau about the latest developments in the field of multiple myeloma, and we went through the latest EHA-ESMO guidelines.
And this is really amazing because in the transplant-eligible patient, we discussed the advent and efficacy of novel induction regimens, the quadruplet regimens with anti-CD38 and the triplet VTD or VRd, dara-VTD, daratumumab-VRd...
During the last meeting of the European School of Hematology, I had a lovely chat with Professor Philippe Moreau about the latest developments in the field of multiple myeloma, and we went through the latest EHA-ESMO guidelines.
And this is really amazing because in the transplant-eligible patient, we discussed the advent and efficacy of novel induction regimens, the quadruplet regimens with anti-CD38 and the triplet VTD or VRd, dara-VTD, daratumumab-VRd. We also discussed the advances in the non-transplant-eligible population and, obviously, the use of anti-CD38-based combinations is also now becoming more and more standard of care, dara-rev-dex, daratumumab-lenalidomide-dexamethasone, or daratumumab-bortezomib-melphalan-prednisone, dara-VMP. We also, of course, discussed the different treatment options at the time of relapse with a special focus on the lenalidomide-refractory patient, where we do have now some good and effective combinations like daratumumab-carfilzomib-dex. This is a CANDOR trial. Isatuximab-carfilzomib-dex, the IKEMA trial, or daratumumab-pomalidomide-dexamethasone, APOLLO trial, or isatuximab-pomalidomide-dex. This is the ICARIA trial.
Last but not least, of course, we could not skip the role of immune therapy, whether CAR T-cells. One construct has just been approved, but also the advent of bispecific antibodies, but also antibody-drug conjugates. So really it’s a fascinating new era for multiple myeloma, and this is really great news for the patient and for all of us in the myeloma space.
Read more...
